HighTower Advisors’s Theriva Biologics TOVX Stock Holding History

HighTower Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-4	Closed	-$8K	–	2418
2018 Q2	$8K	Hold	4	–	–	﹤0.01%	2157
2018 Q1	$12K	Buy	4 +2	+100%	+$7.61K	﹤0.01%	2078
2017 Q4	$9K	Sell	2 -3	-60%	-$18.7K	﹤0.01%	2188
2017 Q3	$44K	Sell	5 -2	-29%	-$11.6K	﹤0.01%	2093
2017 Q2	$32K	Buy	7 +2	+40%	+$9.96K	﹤0.01%	2049
2017 Q1	$29K	Buy	5 +1	+25%	+$6.98K	﹤0.01%	1951
2016 Q4	$29K	Sell	4 -1	-20%	-$10.3K	﹤0.01%	1845
2016 Q3	$72K	Hold	5	–	–	﹤0.01%	1766
2016 Q2	$76K	Hold	5	–	–	﹤0.01%	1624
2016 Q1	$104K	Hold	5	–	–	﹤0.01%	1900
2015 Q4	$102K	Hold	5	–	–	﹤0.01%	1840
2015 Q3	$97K	Buy	5 +2	+67%	+$49.2K	﹤0.01%	1735
2015 Q2	$78K	Buy	3 +1	+50%	+$20.1K	﹤0.01%	1434
2015 Q1	$37K	Buy	+2	New	+$35.7K	﹤0.01%	1555

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

HighTower Advisors's TOVX Position: Q3 2018 in Review

HighTower Advisors sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 4 shares — an estimated $8K sold.

HighTower Advisors first reported a position in TOVX in Q1 2015 and held it in 14 quarters. The position peaked at $104K in Q1 2016. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

HighTower Advisors reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
HighTower Advisors sold 4 Theriva Biologics shares in Q3 2018, an estimated $8K.
HighTower Advisors first reported a position in Theriva Biologics in Q1 2015 and held it in 14 quarters.
HighTower Advisors's Theriva Biologics position peaked at $104K in Q1 2016.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on HighTower Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.